Welcome to article directory Crox. Here You can find interesting and useful information on most popular themes.

There are 188 published articles and 1 registered authors in our article directory.

  • Crox (123)
    • No categories

Recent Articles

Actos Warning Proclamation

By admin | Published January 26, 2012

Actos Warning : Tobacco smoking and occupational exposure have been the two major factors related to BC risk; however, not all smokers develop BC and not all cases of BC occurred in smokers or patients with chemical exposure. It has been proposed that there could be factors other than environmental that could affect the incidence on urothelial tumors. In fact, as for many other cancers, molecular researchers are trying to establish genetic alterations linked to carcinogenesis that could justify genetic predisposition.An important research has been conducted in patients with BC in relation to smoking and chemical exposure , trying to identify those patients with higher sus­ceptibility of being affected by environmental carcinogens. Aromatic amines were established carcinogens for urothelium.

 

More information on Actos Warning

They could be inactivated by acetylation pathway, and it has been postulated that those patients with slow acetylation capability were more susceptible to BC than those that are rapid acetylators. NAT-1 and NAT-2 are N-acetyltransferase genes located on the short arm of human chromosome 8 and they are involved in amines inactivation. Reduction in NAT-2 activity has been suggested as mechanism for BC predisposition among patients exposed to environmental carcinogens such as aromatic amines.A number of SNPs have been reported in NAT-2 coding exon, as well as over 35 NAT-2 haplotypes have been identified (Hein 2006). Several of these haplotypes corresponded to NAT-2 slow acetylator phenotype and NAT-2 slow acetylation genotype has been related to higher risk of BC.

Information from other sources on Actos Warning

The Spanish Bladder Cancer Study is a hospital-based case-control study on BC conducted in five different areas in Spain that included 1150 cases and 1149 controls. They evaluated in this great population the association of several polymorphisms in NAT and GST genes with BC risk and their interaction with cigarette smoking. In addition, they reported a metaanalysis of 29 studies of NAT-2 and BC including 5096 cases and 6519 controls. They demonstrated that NAT-2 slow acetylators had a 40% increase in BC risk compared to rapid/intermediate acetylators with an OR of 1.4 (95% CI, 1.2-1.7). They could also demonstrate a significant multiplication interaction between NAT-2 slow acetylation genotype and cigarette smoking, that is, NAT-2 slow acetylators were especially susceptible to the adverse effects of ciga­rette smoking on BC risk. On the other hand, the metaanalysis performed corrobo­rated their own data, being the summary on relative risk for NAT-2 slow acetylators compared to rapid/intermediate acetylators of 1.4 (Garcia-Closas et al. 2005).Other SNPs in different genes have been studied. Nucleotide excision repair (NER) pathway is a complex mechanism for repairing DNA damage and subse­quently for preventing carcinogenesis. NER pathway included several genes, and different SNPs on those genes have been related to an increase in BC risk. Twenty- two SNPs on seven NER genes were evaluated in 1150 cases and 1149 controls included in The Spanish Bladder Cancer Study. Four of these 22 SNPs in NER genes could be significantly related to a small increase in BC risk and interestingly it could be demonstrated as a stronger association between BC and polymorphism in ERCC2 gene (ERCC2 R156R) for never-smokers compared with ever-smokers (Garcia-Closas et al. 2006).

Other study including 696 patients with BC and 629 controls evaluated the asso­ciation with BC risk of a comprehensive panel of 44 SNPs in genes of NER path­way and genes involved in cell cycle control. They concluded that patients with higher numbers of variants in NER genes rather than single polymorphism are at increased risk for BC (Wu et al. 2006).

 

Our use of the term or terms Actos Warning is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Warning visit our site often.

http://www.seedol.com

Posted in Crox | Tagged , | Leave a comment

Actos and Bladder Cancer News Flash

By admin | Published January 26, 2012

Actos and Bladder Cancer : Traditionally, the surgery is performed through a lower abdominal incision in the midline from just below the umbilicus (i.e., “belly button”). Hospitalization for this procedure is generally between 5 and 10 days, and up to 6 weeks are needed for complete recovery. In recent years minimally invasive surgical approaches that replicate the technique of open radical cystectomy have been developed. Both laparoscopic and robotic-assisted radical cystectomies are currently being performed at highly specialized cen­ters. The principles of the surgery are the same, but the procedure is performed through smaller incisions using laparoscopic instruments. Using robotic assistance, your surgeon is able to perform complex operations with higher precision, under magnification. These approaches offer die potential advantage of a shorter recovery time, less blood loss, and less postoperative pain,

 

More information on Actos and Bladder Cancer

A pelvic lymph node dissection should be performed at the time of your surgery. This involves removal of the lymph node tissue in the most common areas of bladder cancer metastasis (spread of the cancer). The pelvic lymph node dissection has two important roles: to stage the cancer and to guide therapy. Individuals who are found to have cancer in the lymph nodes at the time of surgery generally require additional therapy such as chemotherapy. Studies have shown that up to 30 percent of patients with disease- positive lymph nodes who undergo a pelvic lymph node dissection will be free of disease at 5 years. Although there is debate among urologists as to exactiy how extensive ofapelvic lymph node dissection should be performed, there is no de­bate that one should be performed. Although a pelvic lymph node dissection can add an additional 30-90 minutes to your procedure time, there is little additional morbidity associ­ated when performed by an experienced surgeon.

 

Information from other sources on Actos and Bladder Cancer

Regardless of the approach, anyone who undergoes a radical cystectomy will require a form of urinary diversion because the bladder will no longer be there to store urine. This can have a significant psychological and functional impact on an individual’s quality of life. Patients are often hesitant to undergo definitive surgery because of the anxiety associated with long-term urinary diversion. There are two main types of urinary diversion: continent and noncontinent. Both forms require surgically removing a segment of bowel (most commonly the small bowel) from your gastrointestinal (GI) tract and plugging the ureter from each kidney into this segment of bowel to provide drainage of urine. Noncontinent diversions (ileal conduit) are those in which the piece of bowel is brought up through the abdominal wall to a stoma and the urine drains contin­uously into a drainage bag. This is die most common type of urinary diversion performed in the United States. This procedure requires approximately 8 to 10 centimeters (3 to 4 inches) of small bowel, which is far less than that used for continent urinary diversions. Although the obvious dis­advantage of this procedure is its lack of continence and need for a continuous drainage bag, it has less short- and long-term complications than that of the continent diver­sion. An external urinary drainage appliance is very well tolerated and patients adapt to them very quickly.

 

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

Actos and Bladder Cancer

Posted in Crox | Tagged , | Leave a comment

Actos Bladder Cancer Broadcast

By admin | Published January 26, 2012

Actos Bladder Cancer : Not resting on their laurels, the clinical research community has moved forward and is now testing a new combination that adds paclitaxel, another active drug mentioned above, to the gemcitabine- cisplatin regimen. A three-drug combination (gemcitabine-cisplatin- paclitaxel) has been compared to the two-drug standard, to see whether this produces better cancer shrinkage and improved survival. In June 2007, the first report of this trial was made public. It indicated that the three-drug combination offered no significant benefit compared to gemcitabine-cisplatin and was associated with more side effects.

Another new agent, pemetrexed, also targets the division and reproduction of cancer cells, and has a relatively gentle profile with regard to side effects. It is being tested in patients who have already been treated with gemcitabine and cisplatin to see whether it will cause tumor shrinkage. Early reports are promising, but its true use­fulness is not yet known, and it has not yet been assessed by the Food and Drug Administra tion, which must give formal approval for its use in the treatment of bladder cancer.

In addition to the use of chemotherapy, another class of anti-can- cer agents, the so-called growth inhibitors or targeted agents, is being tested in patients with advanced bladder cancer. It is known that pro­teins located on the surface of cancer cells can control the rate of DNA production and division and stimulate cancer-cell growth. An example is the epidermal growth factor receptor (EGFR), which sits on the surface of some bladder-cancer cells and helps to control the rate at which they grow and divide. Inhibitors of the function of EGFR (and of the genes that control its production) have been developed and are known to slow or stop the growth of some cancer cells.

More information on Actos Bladder Cancer

You may be alarmed if your doctor suggests the possibility of par­ticipating in a clinical trial Does it mean that you have no hope? What should you do? How should you respond? It’s important not to dismiss the idea out of hand. The words experimental, research, and human volunteer can be upsetting, particularly at a time when you are dealing with the emotional issues surrounding a diagnosis of advanced cancer. But treatments in clinical trials can often be highly beneficial to those who volunteer. You and your loved ones should talk with your medical team members about the kind of clinical trial they are recommending and why it may benefit you. In fact, several studies have shown that patients participating in clinical trials have better outcomes than those found in the community at large. However, this also may be due to the types of patients who agree to participate in trials.

Does referral to a clinical trial mean that there is no hope of your surviving this illness? Not at all! There is always hope of survival, and any doctor can tell you about people who have responded positively to treatment and not only survived, but thrived. Being in a clinical trial doesn’t mean that you won’t continue to receive medical treatment; you wall, and since it’s a voluntary process, you have the right to stop participating in the trial at any time.

As with any aspect of your treatment plan, you make the decision about whether to proceed. Don’t feel pressured to participate in a trial if it doesn’t feel right for you, but do give it objective thought and consideration. How do you begin thinking through the decision on whether to participate in a trial?

Information from other sources on Actos Bladder Cancer

Probably the first question that comes to your mind is whether clinical trials are safe. Scientists and medical investigators work hard to ensure that they are as safe as possible. The medical community and the U.S. Department of Health and Human Sendees have put rules in place ensuring that every clinical trial is highly regulated and reviewed by health-care professionals, who determine that the trial is designed and conducted in compliance with federal regulations gov­erning research on human volunteers. Everything about the trial, from the doctors involved to the people who volunteer and the treat­ment being tested, is subject to strict review and monitoring. However, it is important to understand that some clinical trials do carry increased risks.

As with any treatment, you’ll want to ask about possible risks, ben­efits, side effects, how the treatment works, and what results doctors expect from the study.You’ll want to know who is conducting the clin­ical trial and what kind of oversight is in place. Also ask what is expected of you. Where will you go for the treatments? How often will you go? Are there more tests or office visits than you might have with standard treatment? Who administers the treatments and how are the results measured? Do you have to report regularly to those running the trial? Who pays for it all? Will there be extra costs to you as a result of your participation? Will the team conducting the trial (or the doctors involved) stand to benefit personally from the results of the trial or its conduct?

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Posted in Crox | Tagged , | Leave a comment

Actos Side Effects News

By admin | Published January 26, 2012

Actos Side Effects : CAN CYTOLOGY BE USED INSTEAD OF CYSTOSCOPY TO RULE OUT BLADDER CANCER?

Urinary cytology is the examination of urine using special stains to look for cancer cells. These cells would have been those that have broken off (exfoliated) from the lining of the urinary tract. Voided urine is sent for analysis. First voided morning urine should not be used as there is a higher rate of cellular degeneration. To enhance the yield of cells, the bladder can be barbotaged (flushed). Cytology is most useful for high grade or aggressive tumors and for those with carcinoma in situ (CIS). In low to intermediate grade tumors, cytology may not be positive because these tumors may not exfoliate cells into the urine. In addition, if low grade tumor cells are exfoliated, they may appear to the pathologist to be identical to normal bladder cells. Due to the limitations of sensitivity of cytology, it is not a very good screening test, but proves to be valuable in following some individuals who have already been diagnosed and treated for bladder cancer.

Because a positive cytology is very specific for cancer, it is highly predictive of transitional cell cancer even if no tumor is visible during cystoscopy. Additional information can be obtained with urine cytology. The DNA content and measurement of the amount of abnormal DNA can be determined. In general, as the amount of abnormal DNA is increased, the prognosis is worsened.

More information on Actos Side Effects

ARE THERE ANY OTHER URINE TESTS THAT ARE HELPFUL IN MAKING THE DIAGNOSIS?

There has been continued research and a subsequent array of urine tests to screen for bladder cancer. Some of these newer tests include:

Bladder Tumor Antigen (BTA): measures basement membrane protein antigen released into the urine, a protein from the bladder wall.

NMP22: measures nuclear matrix protein 22

Aura Teck FDP: measures fibrin, fibrinogen degradation

products

Telomerase: measures the enzyme used to preserve telomeres (the ends of chromosomes required to continue cell division) Hyaluronic Acid, Hyaluronidase: substances which have a role in blood vessel growth in bladder tumors and tumor progression. [1] Research goes on and newer tests may prove to be both more sensitive (positive if cancer is present) and more specific (not positive for other reasons). At this time, none of the urine tests are sensitive enough to take the place of cystoscopy in the initial evaluation of an individual suspected to have bladder cancer. In general, cytology as an adjunct to cystoscopy is more helpful than any of the urine bladder cancer tests to date.

AS PART OF MY INITIAL WORK UP, MY PHYSICIAN HAS ORDERED A CAT SCAN. WHAT’S THE PURPOSE AND ARE THERE ANY ALTERNATIVES?

When an individual has gross hematuria or persistent microscopic hematuria, a complete assessment of the urinary tract is required. Although cystoscopy is the test of choice for examination of the bladder, imaging studies are required to make sure there is no disease in the upper tracts (kidneys and ureters). Bleeding can be caused from many different disorders including transitional cell carcinoma of the upper tracts, kidney or ureteral stones, or renal cell carcinoma (cancer of the parenchyma or fleshy part of the kidneys). Your urologist has a number of options to choose from. There are advantages and disadvantages of each.

Intravenous pyelogram (IVP) is accomplished by injecting a contrast agent into your vein and then obtaining X ray images. The contrast is excreted by your kidneys, subsequently filling the lumen of the kidneys, ureters and the bladder. The contrast allows one to see subtle filling defects within chambers of the urinary tract, possibly representing tumor, stone or blood clot. Tumors of the fleshy part of the kidneys can also be seen. The study also allows for an assessment of renal function. It is a sensitive test for renal obstruction, which can occur because of cancer. Disadvantages of the study include the possibility of an IV contrast agent allergy, which occasionally may be serious.

You will be asked whether you have a sea food allergy, a known allergy to iodine or to IV contrast. If this is the case, you may need to be premedicated prior to the exam to avoid a reaction. Although the study is quite useful at visualizing the upper tracts, it is not very good at picking up subtle tumors on the bladder surface. If your kidneys do not function well (you have renal insufficiency), the contrast may cause harm to your kidneys and the imaging will not be as good. For pregnant women, any X ray exam could be potentially damaging to the fetus and therefore, will not be performed.

 

Information from other sources on Actos Side Effects

Ultrasonography can check for a kidney tumor, stone, or obstruction. Bladders filled with urine can be scanned. There is no contrast or X rays involved, and therefore the study can be accomplished in those with renal disease, contrast allergies or for women who are pregnant. Although larger tumors of the bladder are often visible, it is not a good study to rule out urothelial cancer (transitional cell cancer of the urinary tract lining) since smaller tumors or flat tumors in the lining are not visible. Also, other conditions such as enlarged folds in the bladder or enlarged prostates can be confused with bladder tumors. Ultrasound exams are generally fast, painless, and relatively inexpensive. An ultrasound combined with cystoscopy plus cytology (to rule out cancer cells) is a reasonable assessment for those with a low likelihood of having upper tract disease.

CT Scan or CAT (computerized axial tomography) provides a computerized cross sectional visualization of the abdomen and pelvis. X ray images are synthesized into exquisitely detailed images. The CT scan can be done with or without IV contrast, and therefore has the same limitations as IVP in those with allergies to contrast or renal insufficiency. These studies are excellent for finding renal cell cancers and stones within the kidneys and ureter, but not very good at delineating cancers of the lining. CT scan is often an important part of staging bladder cancer, determining whether the cancer has spread.

Magnetic Resonance Imaging (MRI) is a technology which uses strong magnets to provide detailed images of your internal organs. Like ultrasound, this study has no known harmful effects on the body. It does not require contrast injection like CT scan and can be done safely in patients with renal insufficiency. It is not generally used for initial screening. Many individuals find the test uncomfortable due to a loud noise heard throughout the test, in addition to the close quarters the machine requires, leading to feelings of claustrophobia. A mild sedative may be required if the test is necessary and the individual experiences these uncomfortable feelings.

Our use of the term or terms Actos Side Effects is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Side Effects visit our site often.

Actos Side Effects

Posted in Crox | Tagged , | Leave a comment

Actos Lawyers Resource

By admin | Published January 25, 2012

Actos Lawyers : Occupational exposure may account for up to 20% of bladder cancers. Those exposed to aniline dyes (used to color fabrics), aldehydes (used in chemical dyes and in the rubber and textile industries) and those using organic chemicals (used in a wide range of occupations) are all at increased risk. Individuals previously treated with radiation to the pelvis or having received cyclophosphamide (a type of chemotherapy) are at markedly increased risk for developing bladder cancer. If your well water is high in arsenic, your risk may also be increased. Studies have also correlated obesity and a high fat diet, especially with increased cholesterol, as a possible contributing factor.

Surprisingly, the answer may be yes. In a recent study, the relationship of diet to cancer was analyzed in a group of47,000 health professionals.[1] In the case of bladder cancer, those who drank the most fluid (greater than 10 cups/day) had half the risk as those who drank the least (less than 5 cups/day). The type of nonalcoholic beverage was less important than the total amount.

For more information on Actos Lawyers follow us on our RSS Feeds.

Although there have been clusters of bladder cancer reported, most researchers believe these may be secondary to risk factors such as smoking and exposure to carcinogens. At this time, there is no convincing evidence bladder cancer risk is hereditary. If an environmental factor caused your cancer and your children are exposed as well, their risk of cancer may be increased. The basic building block of the body is the cell. Cells are specialized to perform a particular function. Skin cells are distinctly different from liver cells which are different from bladder cells. An organ is composed of various cells working in unison to carry out a body function. Cells eventually get old and die. New cells are created by cell division. When cells are behaving normally, they only generate enough new cells to replace the old dying ones. Occasionally, cell growth becomes unchecked. As the cells continue to divide, a tumor (abnormal growth of cells) may form. Such tumors may be benign (no ability to spread beyond their organ of origin) or cancerous (a malignant tumor with the ability to spread beyond their organ of origin and cause harm and possibly death).

Information from other sources on Actos Lawyers

Cell growth is closely regulated by genes which are composed of DNA located in the command center of the cell, the nucleus. When the genes become defective, cell growth can become unregulated, and tumors can develop. Oncogenes, also called cancer genes, can be activated, resulting in uncontrolled cell growth. Other genes which help prevent abnormal cell growth called tumor suppressor genes may be inactivated. Genes can be activated which enhance the tumor cell’s ability to spread throughout the body. The body’s immune system is a critical safeguard against the formation of cancerous tumors, often destroying the abnormal cells before they have a chance to grow and divide.

Cancer cells can spread throughout the body. They can spread through the lymphatic system, composed of lymph channels and lymph nodes, or distantly to other organs or the skeleton via the blood stream (hematogenous spread). In the case of bladder cancer, the cells can also spread by being carried in the urine and implanting in other locations in the urinary tract.

Larger tumors are more likely to spread than smaller tumors. Another critical concern is the grade of the tumor. Normal cells are specialized, differentiated to perform specific function, and have a typical structural arrangement with surrounding cells. As cancers worsen, the cells become less specialized, less differentiated, and lose their normal structural arrangement, resulting in a higher pathologic grade.

Our use of the term or terms Actos Lawyers is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawyers visit our site often.

Actos Lawyers

Posted in Crox | Tagged , | Leave a comment

Actos Cancer Updates

By admin | Published January 25, 2012

Actos Cancer : Radiation therapy for bladder cancer is commonly deliv­ered with a machine that focuses an invisible external beam on die area that requires treatment. The procedure is painless and similar to having an ordinary X-ray done. In the usual approach, your doctors will use your CT scan as a road map of your abdomen and pelvis to pinpoint your tumor and aim the beam at it. In another type of radiotherapy, doc­tors implant a small pellet or needle of radioactive material directly into your cancer. (This is rarely used for bladder cancer these days.)

For more information on Actos Cancer follow us on our RSS Feeds.

When radiation is used alone or with chemotherapy, there is an increased likelihood that your other organs, such as the prostate and uterus, will remain functional, as does your ability to void urine normally and have sex. The intention when chemotherapy ^¿radiotherapy are given is usually to improve the chances of curing the cancer while preserving the bladder and avoiding the need to remove it surgically. This area is still somewhat controversial; some physicians believe that this approach is nearly as effective as surgical removal of the bladder, but others feel that cystec­tomy is the best treatment. The decision of which treatment to pursue depends in part upon the physical fitness of the patient as well as upon the patients personal preferences.

Radiotherapy is not without side effects. Radiation can scar bladder tissue, and the scarring can reduce the amount of urine your bladder can hold as the bladder wall becomes less distensible. As a result you may experience an increase in the number of times you have to urinate, which can be irritating, especially at night. You also may experience an increase in bouts of cystitis.

There has been much discussion in the medical commu­nity about whether the results achieved by radiotherapy are the same as those from cystectomy with respect to achieving cure. We think that when one considers all types of blad­der cancer, in the hands of a highly experienced urologist who specializes in this operation, cystectomy gives better results than radiotherapy. However, there are some patients, particularly those with other significant medical conditions, who will benefit from radiotherapy, despite the possibility of a lower chance of permanent cure. In some centers, such as Massachusetts General Hospital, where the techniques of chemo radio therapy and bladder preservation have been piloted, a urologist will perform a cystoscopy about halfway through the planned course of radiotherapy. If the tumor is shrinking well, radiotherapy will be completed. However, if it appears that the cancer is not responding to radiother­apy, the plan will be abandoned and replaced with a radical cystectomy.

Information from other sources on Actos Cancer

There are no absolute guidelines for follow-up after cystec­tomy. What is right for you will depend on your situation: the type of urinary diversion system you have, whether you received chemotherapy and/or radiotherapy, and what, if any, side effects you are dealing with. A reasonable guide for follow-up, however, is to expect a physical exam, chest X-ray, urine test, and blood work every three months for the first year, every four months for the next two years, and then twice a year for life. We usually recom­mend an annual CT or MRI for the first five years at least.

As with superficial cancer, if you have any of the symp­toms discussed in chapter 1, check in with your doctor. Call your doctor if you have blood in your urine or an increase in the urge or frequency of urination. It might be an infec­tion, but the best thing to do is to make contact without unnecessary delay.

Our use of the term or terms Actos Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Cancer visit our site often.

Actos Cancer

Posted in Crox | Tagged , | Leave a comment

Actos Lawsuit Action

By admin | Published January 25, 2012

Actos Lawsuits : The stage is very important in determining the treatment that you will receive. There is a good barrier between the urothelium and the muscle of the bladder wall. If the tumor is kept within this barrier, the tumor can usually be completely removed with a transurethral resection of bladder tumor (TURBT) (Question 38). If the tumor has become more aggressive, it may figure out how to pass through this barrier. When the tumor has gotten through the protective layer, it becomes much more likely to spread outside of the bladder to other organs or lymph nodes. Once the tumor has gotten through the urothelium, simple scraping of the tumor is not likely to get all of the tumor out, and further therapy will be necessary—either surgery, chemotherapy, or radiation. The option that you and your doctor choose will depend on the extent of spread of the tumor and your overall health status.

Over the years, several different systems have been used to stage cancers. In an effort to ease confusion between different systems, doctors around the world met and decided to create a new staging system that would be relevant for all different types of cancer. This system is called TNM. The letters stand for Tumor size, lymph Node status, and the extent of Metastases.

For more information on Actos Lawsuits follow us on our RSS Feeds.

“Upper tract studies” are evaluations that your doctor does of your kidneys and ureters. The lining of the bladder is the urothelium. The same urothelium also lines the ureters and the inside of the kidneys. The kidneys and the ureters are then also potential locations of transitional cell cancer. The study that your doctor chooses depends on his or her personal opinion as well as the availability of each test at your hospital. Even if the upper tract study is negative, you will likely need to repeat the studies periodically. Patients with low-grade tumors have a low risk (approximately 2%) of developing upper tract tumors. The presence of a high-grade tumor or of diffuse carcinoma in situ, however, carries up to a 40% lifetime risk of developing an upper tract tumor.

Information from other sources on Actos Lawsuits

An ultrasound is often the easiest test to obtain and is therefore popular as a first study. Ultrasound technology generates sound waves and then measures their reflections off of internal structures to produce an image. The same imaging is used for obstetric ultrasounds to produce an image of the fetus. There is no radiation with an ultrasound. An ultrasound is very good for showing tumors and stones in the kidneys and for showing obstruction of the ureter causing hydronephrosis. It is not as good for showing small tumors inside the ureter or renal pelvis, and thus a second kind of study is usually needed in addition to the ultrasound.

Our use of the term or terms Actos Lawsuits is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuits visit our site often.

Actos Lawsuit

Posted in Crox | Tagged , | Leave a comment

Actos Lawyer Data

By admin | Published January 25, 2012

Actos Lawyer: Approximately twenty percent of patients with bladder cancer will complain of irritative voiding symptoms. These symptoms include urinary urgency (a need to rush to the bathroom), burning and urinary frequency. These same symptoms are present in other urologic conditions such as infection, bladder instability and prostatic enlargement in men. These symptoms are most commonly associated with a diffuse superficial form of transitional cell cancer of the bladder called CIS (carcinoma in situ). Unfortunately for some, their diagnosis may be delayed since these symptoms are present in so many other diseases.

Cystoscopy (examination of the bladder) is usually the first step in making the diagnosis of bladder cancer. Given the signs and symptoms suggesting bladder cancer, or an X ray or ultrasound revealing a possible bladder tumor, cystoscopy is a must. Cystoscopy can be accomplished with either a flexible cystoscope or a rigid scope. The flexible cystoscope is composed of small optical fibers encased by a plastic sheath. A rigid scope has glass lenses within a metal sheath. Both cystoscopes are passed directly through the urethra into the bladder to visualize the inside surface. Cystoscopy can be accomplished in both the urologist’s office or as an outpatient at a hospital or surgicenter.

For more information on Actos Lawyer follow us on our RSS Feeds.

The flexible cystoscope is easier and less painful to pass, especially for males whose urethra is longer and more tortuous than in females. Flexible cystoscopy is readily accomplished in the doctor’s office. A lubricant is applied to the scope to ease passage. Local anesthesia can be squirted into the urethra prior to passing the scope. Discomfort from the cystoscope is usually well tolerated and short in duration. The discomfort usually lasts a few seconds as the scope is passed through the prostate. At that time, you may feel a pressure sensation. In females, passage of the scope is quick and relatively painless.

During the exam, your bladder will be filled with sterile water to allow complete visualization of all the surfaces. You may feel like you have to urinate. During flexible cystoscopy, small biopsies can be obtained. Any bleeding from the biopsy site is readily controlled. The biopsy and cauterization will cause pain for a few seconds. A mild oral sedative can be taken prior to an exam, but is generally not necessary. An entire examination may take only a few minutes. If biopsies are done, the exam will be a little longer. Flexible cystoscopy is very convenient. You can drive yourself to and from the office. After the exam, you can generally go right back to work. If a tumor is found that is too large to treat with a flexible cystoscope, you will be scheduled for an additional procedure at a hospital or surgicenter.

Information from other sources on Actos Lawyer

The rigid cystoscope, although easy to pass in a female is difficult to pass without sedation in a male. The rigid cystoscope allows for generous biopsy specimens and removal of small tumors. Cystoscopy therefore can provide for both diagnosis and treatment at the same time. If a large cancer is found, removal with a resectoscope can be used to remove it at the same time. If multiple biopsies or resection of a cancer is done, spinal or general anesthesia may be required. Since rigid cystoscopy generally causes more discomfort than flexible cystoscopy and requires more anesthetic, you can expect to be out of work at least one day. In addition, someone will need to drive you home from the surgicenter or hospital.

If you are being initially screened for asymptomatic microscopic hematuria, a urologist will often choose flexible cystoscopy as the first step. He is not certain whether or not you have a bladder cancer or other condition causing the hematuria. Flexible cystoscopy will provide that answer in a less time consuming, less painful and more cost effective way than rigid cystoscopy. On the other hand, if there is a high likelihood a tumor is present, it makes sense to do rigid cystoscopy and if required, resection all at one setting. If you are experiencing gross hematuria, flexible cystoscopy does not provide adequate visualization, and rigid cystoscopy is warranted. Many urologists use both types of cystoscopes, but some do not have the flexible cystoscope in their office.

Our use of the term or terms Actos Lawyer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawyer visit our site often.

Actos Lawyer

Posted in Crox | Tagged , | Leave a comment

Mesothelioma Lawyer Breaking News

By admin | Published January 25, 2012

Mesothelioma Lawyer : Simian virus 40, or SV40, is a virus that has been asso­ciated with the development of malignant mesothe­lioma. This virus is found in rhesus monkeys and is now widespread among humans. The way this virus was transferred from monkeys to humans is uncertain, but it is postulated that some of the transfer occurred from 1954 to 1963 through SV40-contaminated polio vaccines administered worldwide. Those people who received the injectable form of the polio vaccine are believed to be those at greatest risk. This vaccine doesn’t folly explain the transfer of this virus, because many humans who could not have received the contaminated vaccines are now infected with the SV40 virus. One theory that has been proposed is that the SV40 virus continues to be transferred from monkeys to humans or that humans can pass the virus from person to per­son. Propecia Lawsuit

For more information on Mesothelioma Lawyer follow us on our RSS Feeds.

The latter theory has been supported by data showing that SV40 can be excreted in human feces, breast milk, and semen. It is unlikely that this virus acts alone in the development of mesothelioma as most cancers have multiple risk factors associated with their development, and most mesotheliomas occur in asbestos exposed individuals. Instead, it is more likely that asbestos and SV40 may act together to develop into mesothelioma. Although rare, cases of mesothelioma have been found following radiation exposure to the chest and abdomen. These individuals were usually treated in the past with radiation therapy for a malignancy of the lymph glands known as lymphoma.

Lastly, there is an indication that a person’s own genes can play an important role in determining who is sus­ceptible, or vulnerable, to these mineral fibers and will then develop mesothelioma. It is hoped that doctors will be able to find the specific susceptibility gene in the future and that this may lead to the development of new prevention and treatment strategies to better control this disease. Exposure to asbestos is the link to the development of mesothelioma. People who end up with this disease usually have had some type of previous exposure to asbestos. How this works is not fully understood. It is thought that asbestos fibers are inhaled and first travel through the upper air passages, which include the throat, the trachea (windpipe), and the large bronchi (large breathing tubes of the lungs). These airways are lined with mucus, and therefore most of the fibers are cleared from these upper airways by sticking to this mucus and being coughed up or swallowed. When the fibers continue to travel and reach the small airways (the alveoli), the body’s immune system is able to sur­round, engulf, and remove the smaller fibers by a process known as phagocytosis. Actos Lawsuit

 

Information from other sources on Mesothelioma Lawyer

The large, long, thin fibers cannot be cleared as easily and may eventually reach the pleura (the lining of the lung and the chest wall), where they may irritate and injure the cells and lead to the development of calcium containing plate­like structures on the pleural lining (pleural plaques), fibrosis (scar tissue formation), or mesothelioma. These same asbestos fibers can also damage cells in the lung itself, which can lead to asbestosis (scar tissue in the lung) and/or lung cancer. Patients with these pleu­ral plaques seem to be at highest risk for developing mesothelioma.

The best way to prevent mesothelioma is to decrease one’s exposure to asbestos in the workplace, at home, and in the environment. The federal government is responsible for developing regulations that deal with asbestos exposure in the workplace. The agency that issues these regulations is known as the Occupational Safety and Health Administration (OSHA). Employ­ers are required to follow these regulations, and there­fore workers who are concerned about asbestos exposure should be discussing these concerns with their employers or union. Also, employees should be using all protective equipment provided to them by their employers and following recommended safety procedures and practices while at work.

Our use of the term or terms Mesothelioma Lawyer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Mesothelioma Lawyer visit our site often.

Mesothelioma Lawyer

Posted in Crox | Tagged , | Leave a comment

Multaq and Liver Damage Information

By admin | Published January 25, 2012

Multaq and Liver Damage: The most effective treatment of chronic HCV is antiviral ther- apy—that is, medication that targets a virus. Interferon, a widely known antiviral discussed earlier in this chapter, is the treatment of choice for chronic HCV. Pegylated interferon in combination with ribavirin-—-the most common treatment-—is the most effective treatment for chronic hepatitis C, but the side effects can be substantial. Flulike symp­toms (fever, chills, muscle and joint pain, fatigue, weakness) are common, and doctors will prescribe medications to combat these symptoms if they become debilitating. It is also important for patients to maintain their activity levels to build a little muscle and be able to muster the energy to get through the day. Adequate fluid intake is also essential. This is a simple and often overlooked strategy. Many patients report that substantially increasing their daily fluid intake is the most effective method in combating the fiulike side effects that plague pegylated interferon therapy.

Depression, insomnia, irritability, and even confusion are expe­rienced by more than half of patients undergoing interferon ther­apy. The depression is considered to be somewhat different from classic major depression, but afflicted patients may benefit from a course of antidepressants such as citalopram (brand name Celexa) or sertraline (brand name Zoloft).

Other side effects that don’t seem to follow any regular pattern include headaches, vision problems or dry eyes, weight changes, brictle nails, insomnia, changes in blood levels, a burning sen­sation in the mouth (known as stomatitis), decreased sex drive, and menstrual irregularities. To some degree, these symptoms are manageable. But in some patients, the side effects can be severe, and supportive medications are able only to “take the edge off” Although treatment may be difficult, physicians who regularly treat chronic hepatitis C are well versed in managing side effects. Key to successful outcome is maintaining the proper dose of medication to ensure that patients have the best possible chance to permanendy rid their bodies of the virus.

For more information on Multaq and Liver Damage follow us on our RSS Feeds.

Because of chronic HCV’s complicated makeup—-the genotypes outlined above—pegylated interferon therapy must be custom­ized to each patient. Therapy duration is dictated by the genotype. Pegylated interferon is used, if possible, in combination with riba­virin. The only time ribavirin is not used is when there is a medical contra-indication, such as chronic kidney (renal) failure requiring dialysis or a severe allergy to ribavirin. How well the patient responds to antiviral treatment is determined by two simple lab tests. The first is the alanine transaminase (ALT) test. When the ALT decreases and returns to a normal level, it is referred to as a biochemical response. This does not always occur, but it is a con­sidered a good sign. The most important test in determining treat­ment success is the HCV RNA, or viral load test. The decline in the viral load is the most crucial aspect of therapy. Typically, a patient is tested at the outset, to determine a baseline or pre-treatment viral load, and then retested to measure against the subsequent viral loads as treatment progresses.

Four weeks after treat­ment begins, first viral load is measured. If a patient’s viral load is un-detectable at one month, the results are called a rapid virologie response, or RVR. People who achieve an RVR are called super responders. They have an excellent chance of eradicating the virus after they complete their treatment. A small subset of patients who achieve an RVR can sometimes stop treatment early. The deter­mination to stop treatment early is made on a case-by-case basis, and the patient should be informed of the pros (shorter treatment duration, lower cost, and less side effects) and cons (slightly lesser chance for sustained response) of this approach.

Information from other sources on Multaq and Liver Damage

After 12 weeks (three months) of therapy, viral load is mea­sured again. The outcome of this viral load test is referred to by different names, depending on the results. When the virus is unde­tectable after three months of therapy, the condition is described as a complete early virologie response (cEVR). If the viral load has declined by two logs but is still detectable, the data is referred to as a partial early virologic response (pEVR).

People who achieve a partial or complete early virologic response continue drug therapy. Those who do not achieve a two-log reduc­tion after 12 weeks are called nonresponders (NRs). Unfortunately, nonresponders have less than a 3 percent chance of achieving a sustained viral response even if they complete the full course of therapy. Therefore, therapy is stopped for nonresponders after three months if they do not obtain a two-log reduction.

For patients who remain on therapy, the next viral load test is taken after six months (24 weeks) of therapy. If this test indicates a detectable viral load, as a rule, treatment is stopped because these patients will not achieve treatment success even if they complete a full 48 weeks of therapy.

After 48 weeks of pegylated interferon and ribavirin, another viral load test is performed. Referred to as the end-of-treatment response (ETR), this viral load measurement marks the end of therapy and the beginning of a waiting game. For treatment to be considered a success, the viral load must remain negative for at least six months after the end of therapy. Unfortunately, some patients relapse and test positive during this six-month period. Relapsers should follow up and discuss their situation with a hepatologist and consider options such as enrollment in research clinical trials of new and experimental therapies can be considered.

Our use of the term or terms Multaq and Liver Damage is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq and Liver Damage visit our site often.

Multaq and Liver Damage

Posted in Crox | Tagged , | Leave a comment